NDAINJECTIONINJECTABLE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAPLON (rapacuronium bromide) is an injectable neuromuscular blocking agent approved by the FDA in 1999 for use during anesthesia. It functions as a rapid-onset, short-acting paralytic agent used to facilitate intubation and surgical procedures. The drug works by competitively blocking acetylcholine at the neuromuscular junction.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a team likely focused on transition planning and generic defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RAPLON currently shows zero linked job openings, reflecting its mature lifecycle stage and minimal growth trajectory. Career opportunities on this product are limited and primarily focused on sustaining existing market position rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on RAPLON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.